ABSTRACT Cure Glomerulonephropathy (CureGN) is a National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)-sponsored, multi-center international consortium established in 2013 to study the natural history of glomerular diseases (minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, and IgA nephropathy), understand their underlying biology, develop biomarkers to resolve disease heterogeneity, and ultimately improve therapeutic options. CureGN has made progress in: 1) establishing a large, ethnically diverse longitudinal observational cohort of glomerular disease patients; 2) creating a rich, well-curated clinical data set and linked biospecimens; 3) establishing the largest repository of digital kidney biopsies; and 4) an infrastructure that will facilitate translational and clinical research by core and ancillary study scientists. Defining the genetic and genomic landscape of the diseases studied by CureGN has been a core aim from the initiation of the study and the emerging genetic information of CureGN participants is currently utilized by a multitude of core and ancillary studies. As CureGN will continue to recruit a limited set of patients, the blood biospecimens from the enrollemtn visit will need to be processed so that isolated DNA and RNA can be submitted to the NIDDK central biorepository for use by the scientific community. This supplemental funding request asked to cover the isolation costs for up to 1000 patients (200 patients already recruited, and up to 800 to be recruited depending on the recruit to replace needs of CureGN 2). CureGN will use a centralized service by Precision for Medicine who has an outstanding track record for processing excellence and quality control metrics in place. This service provider will also be able to access the biosamples from the incoming CureGN shipments to the NIDDK CBR, reducing sample transfer logistical burden and opportunity for sample losses substantially.